Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Bergemalm

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Journal of Crohn'S & Colitis|December 1, 2021
Prognostic Biosignatures at Ileocecal Resection: Hope or Reality?Benita Salomon, Daniel Bergemalm, Jonas Halfvarson
Scandinavian Journal of Gastroenterology|January 30, 2025
Insulin sensitivity in moderately severe to acute severe ulcerative colitisDaniel Bergemalm, Bayar Baban, Olle Ljungqvist, et al.
Gastroenterology|June 25, 2025
ReplyOlle Grännö, Daniel Bergemalm, Benita Salomon, et al.
Plos One|March 22, 2017
Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBDDaniel Bergemalm, Robert Kruse, Maria Sapnara, et al.
Therapeutic Advances in Gastroenterology|July 28, 2025
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH studyLinda Ryen, Isabella Visuri, Sara Karlqvist, et al.
Plos One|October 6, 2017
Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profilesErik Andersson, Daniel Bergemalm, Robert Kruse, et al.
Scandinavian Journal of Gastroenterology|October 26, 2023
Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levelsJoel Thunberg, Olle Grännö, Daniel Bergemalm, et al.
Annals of Neurology|April 15, 2008
Inclusions of amyotrophic lateral sclerosis-linked superoxide dismutase in ventral horns, liver, and kidneyP Andreas Jonsson, Daniel Bergemalm, Peter M Andersen, et al.
Lakartidningen|August 14, 2024
[Health-related quality of life for patients with inflammatory bowel disease requires more than anti-inflammatory treatment]Stefan Lindgren, Sven Almer, Daniel Bergemalm, et al.
United European Gastroenterology Journal|August 21, 2025
Environmental and Inflammatory Factors Drive Perinuclear-Antineutrophil Cytoplasmic Antibodies (pANCA) in Ulcerative Colitis: A European Twin StudyDaniel Bergemalm, Karin Amcoff, Marie J Pierik, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Journal of Crohn'S & Colitis|December 1, 2021
Prognostic Biosignatures at Ileocecal Resection: Hope or Reality?Benita Salomon, Daniel Bergemalm, Jonas Halfvarson
Scandinavian Journal of Gastroenterology|January 30, 2025
Insulin sensitivity in moderately severe to acute severe ulcerative colitisDaniel Bergemalm, Bayar Baban, Olle Ljungqvist, et al.
Gastroenterology|June 25, 2025
ReplyOlle Grännö, Daniel Bergemalm, Benita Salomon, et al.
Plos One|March 22, 2017
Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBDDaniel Bergemalm, Robert Kruse, Maria Sapnara, et al.
Therapeutic Advances in Gastroenterology|July 28, 2025
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH studyLinda Ryen, Isabella Visuri, Sara Karlqvist, et al.
Plos One|October 6, 2017
Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profilesErik Andersson, Daniel Bergemalm, Robert Kruse, et al.
Scandinavian Journal of Gastroenterology|October 26, 2023
Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levelsJoel Thunberg, Olle Grännö, Daniel Bergemalm, et al.
Annals of Neurology|April 15, 2008
Inclusions of amyotrophic lateral sclerosis-linked superoxide dismutase in ventral horns, liver, and kidneyP Andreas Jonsson, Daniel Bergemalm, Peter M Andersen, et al.
Lakartidningen|August 14, 2024
[Health-related quality of life for patients with inflammatory bowel disease requires more than anti-inflammatory treatment]Stefan Lindgren, Sven Almer, Daniel Bergemalm, et al.
United European Gastroenterology Journal|August 21, 2025
Environmental and Inflammatory Factors Drive Perinuclear-Antineutrophil Cytoplasmic Antibodies (pANCA) in Ulcerative Colitis: A European Twin StudyDaniel Bergemalm, Karin Amcoff, Marie J Pierik, et al.
Pageof 5